Kornimate/medical-research-clean huggingface dataset:
evaluate aerobic exercise on myocardial fibrosis and intestinal flora in dilated cardiomyopathy diagnosed first time.

Conditions: Cardiac Rehabilitation; Myocardial Fibrosis

Summary: to invegstive the changes of intestinal flora and the improvements of cardiac fibrosis in patients with dilated cardiomyopathy diagnosed for the first time by heart rehabilitation

previous studies have confirmed that aerobic exercise rehabilitation can reduce the rate of readmission of patients with heart failure and improve their cardiopulmonary endurance and exercise ability. however, whether aerobic exercise rehabilitation can inhibit myocardial fibrosis or delay the progress of fibrosis in patients with heart failure has not been reported. at the same time, some studies have shown that the change of intestinal microbial flora may promote the progress of heart failure, and regular aerobic exercise will also lead to the change of intestinal microbial flora, but whether aerobic exercise rehabilitation can improve intestinal microbial flora in patients with dilated cardiomyopathy has not been reported. in our study, patients who were hospitalized for heart failure for the first time and were finally diagnosed with dilated cardiomyopathy were recruited. recruited patients will enter the routine cardiac rehabilitation process and make an individualized aerobic exercise plan according to the cardiopulmonary exercise test. cardiac mri and intestinal microflora changes will be evaluated.

Eligibility criteria:
inclusion criteria: * 1、patients hospitalized for the first time because of heart failure 2、the patient who was definitely diagnosed as dilated cardiomyopathy for the first time exclusion criteria: * 1、other types of cardiomyopathy 2、has been diagnosed as dilated cardiomyopathy. 3、malignant tumor 4、acute infection 5、cannot perform cardiopulmonary exercise test.

Keywords: aerobic exercise rehabilitation myocardial fibrosis human gut microbiome cardiac magnetic resonance
evaluation of xpert mtb/rif assay for the rapid identification of tb and tb rifampin resistance in pulmonary tuberculosis suspects

Conditions: Tuberculosis

Summary: this observational mycobacterium tuberculosis (mtb) diagnostics evaluation study is a longitudinal study of pulmonary tb suspects who are undergoing sputum evaluation for pulmonary tb. the sensitivity and specificity of the xpert mtb/rif (mycobacterium tuberculosis/rifampin) assay performed on the first sputum collected for xpert testing will be compared to gold standard conventional culture methods on two sputum specimens, in hiv-infected and hiv-uninfected participants.


Eligibility criteria:
inclusion criteria: * suspected pulmonary tb (more information on the criterion can be found in the protocol) * men and women age equal to or greater than 18 years * ability and willingness of candidate or legal guardian/representative to provide informed consent * collection of two sputum samples for afb smear and culture collected within 7 days prior to entry. * availability of two samples for xpert mtb/rif testing collected within 7 days prior to entry. * determination and/or documentation of hiv status * for hiv-positive candidates, a cd4+ cell count obtained within 45 days prior to study entry or drawn at the time of entry at any laboratory that has a clia certification or its equivalent. exclusion criteria: * either receipt of ≥48 cumulative hours or three or more doses of anti-tb treatment within 180 days prior to completion of second sputum collection for xpert testing * receipt of more than 7 cumulative days of antibiotics intended for bacterial treatment that may have anti-tuberculosis activity, within the 14 days prior to first sputum collection * active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements
predict: thinking about pregnancy risk in women with kidney disease

Conditions: Chronic Kidney Diseases; Pregnancy Related

Summary: currently, there is no robust evidence about how women with chronic kidney disease (ckd) perceive pregnancy risk. the aims of this research are to understand women with ckd's perception of risk in pregnancy. in order to provide appropriate pre-pregnancy and antenatal counselling including accurate presentation of risk of pregnancy outcomes, it is important to establish how do women with ckd perceive their risk in pregnancy. in addition, to facilitate discussion about pregnancy for women with ckd, it is critical to understand key psychosocial factors influencing their risk perceptions. this study will be conducted in two phases. in phase one, risk perceptions in women with ckd who are contemplating pregnancy will be quantitatively measured with potential influencing psychosocial factors including their illness perceptions, quality of life, anxiety, depression and perceived social support. demographic, pregnancy-intentions, medical and pregnancy histories will also be collected. phase one findings will establish to what extent do women with ckd perceive their pregnancy risk. in phase two, perception of risk, pregnancy intention and behaviour, will be qualitatively explored in women with ckd who perceive high and low degrees of risk. this sub-study will facilitate understanding about which factors and experiences impact risk perception and their relationship with pregnancy intentions and behaviour.

the objectives for this research are: 1. to understand how women with ckd perceive their pregnancy risk. 2. to examine the associations between biopsychosocial factors (demographics, psychosocial factors, renal and pregnancy history) and women with ckd's perception of risk in pregnancy. 3. to examine the relationship between pregnancy-related intention and perception of pregnancy risk in women with ckd. 4. to gain an in-depth understanding of the biopsychosocial factors which influence risk perception and pregnancy-related behaviour, in women with ckd who perceive high and low risk perceptions. to achieve these objectives this study is divided into two phases: phase 1: quantitative assessment of risk perception and biopsychosocial factors in women with ckd phase 2: qualitative exploration of risk perception in women with ckd with high and low risk perception scores

Eligibility criteria:
inclusion criteria: * diagnosed with ckd stages 1-5 according to kdoqi guidelines) * ≥18 years old * planning a pregnancy * adults who have the capacity/capability to provide fully informed consent for the study exclusion criteria: * already established on haemodialysis or peritoneal dialysis * women \ 50 years old * inability or unwilling to give informed consent * does not speak english

Keywords: risk perception
atrovastatin for preventing atrial fibrillation following open cardiac valve repair

Conditions: Heart Valve Diseases

Summary: the purpose of the investigation is to determine whether atrovastatin as anti-inflammatory agent can be effective in preventing from atrial fibrillation incidence in patients whom undergone open cardiac surgery for their heart valve repair.


Eligibility criteria:
inclusion criteria: * greater than 25 y/o * no occurrence of intra- or post-operative cardiopulmonary arrest * not consuming drugs affecting atrial rhythm * having sinus rhythm before surgery * lack of paroxysmal atrial fibrillation history * only undergo heart valve surgery * lack of considerable heart ischemia needed atorvastatin use * routine cares in ward, post-operative ward, and intensive care unit were done exclusion criteria: * lesser than 25 y/o * history of atrial fibrillation * history of taking anti-arrhythmic drugs * history of implementing pacemakers * severe heart failure * renal failure * hepatic failure * severe pulmonary diseases * heart block or bradyarrhythmia * routine cares in ward, post-operative ward, and intensive care unit were not done * performing concomitant cardiac surgery except valve repair * having considerable heart ischemia needed atorvastatin use
effects of thyroid hormone withdrawal on metabolic parameters during radioactive iodine therapy in thyroid cancer

Conditions: Hypothyroidism

Summary: 1. the incidence of differentiated thyroid cancer is increasing in korea. a significant number of them experience severe hypothyroidism in preparation for radioactive iodine (rai) therapy after total thyroidectomy. 2. because the function of thyroid hormone is closely linked with lipid and glucose metabolism, overt hypothyroidism after thyroid hormone withdrawal during rai therapy may induce the changes of metabolic parameters. 3. we investigate the effects of thyroid hormone withdrawal on metabolic and cardiovascular parameters during radioactive iodine therapy in differentiated thyroid cancer.

1. study design measurement of various parameters during hypothyroid state (before 1 month, the day and after 1 month of rai therapy) 2. measurements 1. measurement of metabolic and cardiovascular parameters * glucose profiles : hba1c, fasting glucose level * lipid profiles : free fatty acid, total, ldl-, hdl-, cholesterol, triglyceride * adipocytokines : retinol binding protein(rbp) * 4, leptin, resistin, adiponectin * markers of endothelial and cardiac function : high-sensitivity c-reactive protein(hscrp), homocystein, b-type natriuretic peptide(bnp) * bone turnover markers : ctx, bone alp 2. scoring of symptoms and signs of hypothyroidism (zulewski score) * symptoms * physical signs

Eligibility criteria:
inclusion criteria: * radioiodine therapy after total thyroidectomy in differentiated thyroid cancer * age over 18 exclusion criteria: * kidney failure, liver failure, heart failure * infection * inflammation * autoimmune disease * other chronic disease

Keywords: thyroid cancer hypothyroidism metabolic parameters hypothyroidism after levothyroxine withdrawal
efficacy of ice pack therapy after impacted third molar surgery

Conditions: Impacted Third Molar Tooth

Summary: this study evaluates the effect of cold application after impacted third molar extractions. patients have bilateral impacted third molar tooth included in this study. patients do not applied cold after extraction of third molar on one side and applied cold cold after extraction of third molar on the other side.

extraction of impacted teeth causes a trauma which results in an inflammatory response. some postoperative symptoms may occur such as edema, pain, limitations in mouth opening and dysfunction as a consequence of the wisdom tooth extraction surgery. local cold application reduces the magnitude of postoperative symptoms. the physiological effects of cold application are as follows: vasoconstriction of blood vessels, blood flow to the region decreases, edema and inflammation decreases, slowdown in cell metabolism and a decrease in local oxygen demand due to the vasoconstriction effect of the cold. cold therapy also induces muscle constriction which reduces muscle stress, pain and inflammation.

Eligibility criteria:
inclusion criteria: * bilateral bony mandibular third molar impactions * has no systemic disease exclusion criteria: * different pell-gregory classification of impacted teeth * previous or current gastric ulcer * allergies or hypersensitivities to any common medications * pregnant or breastfeeding patients

Keywords: ice pack therapy, third molar surgery, swelling, pain, trismus
cocoa supplement and multivitamin outcomes study: effects on falls and physical performance

Conditions: Fall; Physical Performance; Fracture

Summary: the cocoa supplement and multivitamin outcomes study (cosmos; nct02422745) is a randomized clinical trial of cocoa extract supplement (containing a total of 500 mg/d flavanols, including 80 mg. (-)-epicatechins), and a standard multivitamin supplement to reduce the risk of cardiovascular disease and cancer among men aged 60 years and older and women aged 65 years and older. this ancillary study is being conducted among participants in cosmos and will examine whether the cocoa extract supplement or the multivitamin supplement improve musculoskeletal health and prevent falls and declining physical performance in the increasing number of older adults in the u.s. with potential for clinical and public health benefits.


Eligibility criteria:
participants in cosmos (nct02422745) who meet the following criteria are eligible to participate in this ancillary study: 1. participants who reported an injurious fall resulting in healthcare utilization (visit to a healthcare provider or hospital) 2. participants who reported recurrent falls (2 or more falls per year)
elecsys he4 chinese reference value study

Conditions: Ovarian Cancer

Summary: aim of this study is to provide specimens for establishing reference values of he4 in an apparently healthy chinese population using the roche elecsys he4 assay tested on variety of elecsys and cobas brand immunoassay analyzers. this reference range will be compared to population of subjects who have signs and symptoms of various benign and malignant diseases, including ovarian cancer. this reference range will also be compared to the levels of he4 in individual subjects who have been diagnosed with ovarian cancer and are being followed longitudinally for recurrence or progression of their disease.


Eligibility criteria:
inclusion criteria (all cohorts): * appropriate clinical data * normal appearance of sample * minimum 0.5 ml volume available exclusion criteria (all cohorts): * \< 18 years of age * insufficient volume * insufficient clinical information * \> 3 freeze/thaw cycles of samples * stored or shipped at \> 0°c * icteric, lipemic, hemolytic, substantial particulates

Keywords: ovarian cancer, he4, normal range
innovative diagnosis and therapy in ldlt patients with high-risk hepatocellular carcinoma

Conditions: High Risk of Recurrence

Summary: the challenge of ldlt to hcc is that tumors with a high risk of recurrence have a high rate of recurrence after liver transplantation, and there is no appropriate treatment to prevent hcc recurrence after transplantation in these patients. using the advance proton therapy or yttrium 90 as a more aggressive down-staging therapy may contribute to change tumor behavior. it can be used to get a better treatment response and tumor necrosis before ldlt. as a result, it will improve recurrence-free survival and overall survival rate, especially in high-risk groups. in addition, lenvatinib is approved for using in patients with advanced liver cancer because its overall survival rate is not less than sorafenib in clinical trials. a new generation of targeted therapies will be applied to adjuvant therapy after ldlt.


Eligibility criteria:
inclusion criteria * targeted therapy is acceptable within 1-2 months after liver transplantation. * immunosuppressive regimen consists of calcineurin inhibitor, mycophenolate mofetil and sirolimus. * all male and female participants must take reliable contraceptive measures during the trial and within four weeks after the end of the trial. * the definition of high-risk patients: * the pet scan is positive before ldlt; * tumors beyond uscf criteria * poorly-differentiated tumor; * the patients who has poor afp response (\ 400 ng/ml after lrt after conventional lrt (rfa、pei or tace) exclusion criteria * life expectancy is less than 3 months * patients are with other malignant tumors simultaneously. * patients are anaphylaxis to the inactive ingredients of lenvatinib or drugs. * pregnant or lactating women (female participants need pregnancy test within 7 days before treatment). * preoperative history of severe cardiovascular disease: congestive heart failure \> nyha grade 2; active coronary heart disease (myocardial infarction occurred within 6 months before entry into the study); severe arrhythmia requiring antiarrhythmic treatment (allowable use of beta-blockers or digoxin); uncontrolled hypertension. * history of hiv infection. * severe clinical active infections (\> nci-ctcae version 3.0). * epilepsy patients requires medication (e.g. steroids or antiepileptic drugs). * patients with kidney diseases requires renal dialysis. * drug abuse, medical symptoms, mental illness or social status that may interfere with participants' participation in research or evaluation of research results. * patients who could not swallow oral drugs, such as those with severe upper gastrointestinal obstruction and need gastric tube feeding.

Keywords: living donor liver transplantation (ldlt) hepatocellular carcinoma (hcc) pet proton yttrium 90 lenvatinib adjuvant treatment
sarcosine or d-serine add-on treatment for chronic schizophrenia

Conditions: Schizophrenias; Psychoses; Psychotic Disorders; Schizophrenic Disorders

Summary: both glyt-1 inhibitors and nmda-glycine site agonists have been demonstrated to be beneficial for chronic schizophrenia patients. the purpose of this study is to compare efficacy and safety of add-on treatment of sarcosine, a glyt-1 inhibitor, and d-serine, an nmda-glycine site agonist, in chronically stable schizophrenia patients who have been stabilized with antipsychotics.

the etiology of schizophrenia remains unclear. schizophrenia patients reveal positive symptoms, negative symptoms, and cognitive impairments. in addition to dopamine system hyperactivity, hypofunction of n-methyl-d-aspartate (nmda) receptor plays a role in the pathophysiology of schizophrenia. consequently, enhancing nmda receptor neurotransmission has been regarded as a novel treatment approach. to date, there have been several reported trials on nmda enhancers. both sarcosine (n-methylglycine, a glycine transporter i inhibitor) and d-serine (a potent nmda-glycine site agonist) showed therapeutic effects in chronically stable patients. interestingly, sarcosine appeared more efficacious than d-serine in acutely exacerbated ones when added-on to antipsychotics. both sarcosine and d-serine yielded excellent safety profiles. it remains unclear whether sarcosine can be also more efficacious than d-serine in the treatment for chronically stable schizophrenia. the aim of this project is to examine the efficacy and safety of add-on treatment of sarcosine vs. d-serine in chronically stable schizophrenia patients who have been stabilized with antipsychotics. in the study, 60-75 schizophrenic patients are recruited into the 6-week trial and randomly assigned into the three groups (2 gm/d sarcosine, 2 gm/d d-serine, or placebo) with a double-blind manner. clinical manifestation (positive and negative syndrome scale \[panss\], side effects and quality of life (qol) are evaluated every two weeks during the trial.. the efficacies of three groups are compared.

Eligibility criteria:
inclusion criteria: * fulfill the criteria of schizophrenia according to the diagnostic and statistic manual, fourth edition (dsm-iv). * agree to participate in the study and provide informed consent. exclusion criteria: * meet dsm-iv criteria of major mood disorder, current substance dependence or mental retardation * history of epilepsy, head trauma or cns diseases * major, untreated medical diseases * pregnancy or lactation

Keywords: schizophrenia sarcosine d-serine nmda
effectiveness of anti-vegf treatments in wet amd in active smokers

Conditions: Wet Age-related Macular Degeneration

Summary: " wet age-related macular degeneration (wet amd)" is characterized by the appearance of new choroidal vessels. several clinical studies have shown the effectiveness of intra-vitreous injections of anti-vegf (bevacizumab, ranibizumab and aflibercept) against these choroidal neovessels. however, some eyes appear to respond less well or be resistant to anti-vegf injections, which affects visual acuity. to improve the clinical management of patients with wet amd, it is important to be able to determine which factors determine the response to anti-vegf treatment. non-modifiable factors such as visual acuity or the patient's age at the time of the first injections, the type and size of choroidal neovascularization, as well as certain genetic polymorphisms are known. two studies, one carried out in korean patients, the other in different centers in singapore, new zealand, australia and switzerland showed that active smoking was associated with a poorer response to intra-vitreous injections of ranibizumab, since smoking is also an already well-known modifiable risk factor for the onset of amd. another study in the netherlands shows a poorer visual prognosis after five years of injection treatment in patients who smoke. this study aims to study the effect of active smoking on the visual prognosis of patients with exudative amd and treated with anti-vegf injections in a belgian cohort.


Eligibility criteria:
inclusion criteria: * chu brugmann hospital patients * patients who received three intra-vitreous injections of ranibizumab, aflibercept or bevacizumab 4 weeks apart as the first intra-vitreous treatment between january 2016 and december 2020. * visual acuity measured before the start of the injections (maximum 1 month) and after the series of three injections (4 to 8 weeks after the last injection) * patients whose smoking status is known and for whom the following history appears: hypertension, diabetes, taking anti-coagulants or anti-aggregants. exclusion criteria: * patients who have already received another intravitreal treatment in the past. * patients who have been treated with dynamic phototherapy before or at the same time as the injections.